Zacks Research Comments on Bristol-Myers Squibb’s Q1 2025 Earnings (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) – Investment analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a report issued on Wednesday, June 26th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings per share of $1.80 for the quarter, up from their prior forecast of $1.79. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.58 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s FY2025 earnings at $6.99 EPS.

Several other research firms have also recently weighed in on BMY. BMO Capital Markets dropped their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, Barclays lowered their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $41.53 on Friday. Bristol-Myers Squibb has a 1 year low of $39.63 and a 1 year high of $65.38. The firm has a 50 day moving average of $42.97 and a 200-day moving average of $48.14. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a market capitalization of $84.19 billion, a P/E ratio of -13.40, a price-to-earnings-growth ratio of 14.20 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the business earned $2.05 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis.

Hedge Funds Weigh In On Bristol-Myers Squibb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMY. Bank of Nova Scotia lifted its position in Bristol-Myers Squibb by 13.7% during the 3rd quarter. Bank of Nova Scotia now owns 208,970 shares of the biopharmaceutical company’s stock worth $12,129,000 after buying an additional 25,153 shares in the last quarter. Morningstar Investment Services LLC lifted its position in Bristol-Myers Squibb by 87.4% during the 3rd quarter. Morningstar Investment Services LLC now owns 7,849 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 3,660 shares in the last quarter. CWA Asset Management Group LLC lifted its position in Bristol-Myers Squibb by 3.6% during the 3rd quarter. CWA Asset Management Group LLC now owns 8,107 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 283 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in Bristol-Myers Squibb by 1,004.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 94,351 shares of the biopharmaceutical company’s stock worth $5,476,000 after buying an additional 85,812 shares in the last quarter. Finally, Waverly Advisors LLC lifted its position in Bristol-Myers Squibb by 11.5% during the 3rd quarter. Waverly Advisors LLC now owns 10,485 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 1,078 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 5.78%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.